Wall Street brokerages predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Sangamo Therapeutics’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.43). Sangamo Therapeutics posted earnings of ($0.17) per share in the same quarter last year, which would suggest a negative year over year growth rate of 100%. The firm is expected to issue its next earnings results on Wednesday, August 14th.

On average, analysts expect that Sangamo Therapeutics will report full-year earnings of ($1.33) per share for the current year, with EPS estimates ranging from ($1.71) to ($0.59). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.88) to $0.05. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.14). Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%. The company had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $27.21 million.

A number of analysts recently weighed in on the company. BidaskClub upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 2nd. ValuEngine downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Zacks Investment Research downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. Finally, Wedbush set a $11.00 price target on Sangamo Therapeutics and gave the company a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $16.00.

In related news, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the sale, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 15,000 shares of company stock worth $160,550. Company insiders own 1.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. raised its holdings in Sangamo Therapeutics by 222.8% during the first quarter. Advisor Group Inc. now owns 4,680 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 3,230 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Sangamo Therapeutics by 29.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,552 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth $102,000. Pearl River Capital LLC acquired a new position in shares of Sangamo Therapeutics in the first quarter worth $94,000. Finally, Merriman Wealth Management LLC acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth $119,000. Hedge funds and other institutional investors own 54.92% of the company’s stock.

Shares of Sangamo Therapeutics stock traded up $0.30 during trading on Wednesday, reaching $10.27. The company’s stock had a trading volume of 1,901,194 shares, compared to its average volume of 2,274,330. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.98 and a quick ratio of 3.98. Sangamo Therapeutics has a 12-month low of $6.26 and a 12-month high of $19.25. The company has a market cap of $1.13 billion, a PE ratio of -14.67 and a beta of 2.89.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Story: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.